Remove Acquisition Remove Competition Remove Sales Remove San Diego
article thumbnail

Biotech Roundup: Deals Gone Wrong, Ethical Red Flags & Bay Goodbyes

Xconomy

Thousands of others will head to San Francisco for BIO, which has a distinct international flavor. But billions of dollars in acquisitions will be left by the side of the road. Bad FDA news for Teva Pharmaceutical and AstraZeneca also threw outsized acquisitions into question. But the U.S. Teva nabbed deutetrabenazine in its $3.2

article thumbnail

Is Your Organization Ready to Become an Ecosystem Driver?

Xconomy

Dominating business-to-consumer sales, Amazon seems ready to take over the world of business-to-business too. In its first year, Amazon Business generated $1 billion in sales. However, there is still room for competition. – Are you great at partnerships and acquisitions? – Is compliance a competence?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Is the Future of Cybersecurity in M&A?

Xconomy

This has been evident with recent acquisitions beyond Symantec and Blue Coat – Avast and AVG, Cisco and CloudLock , IBM and Resilient Systems , and most recently Carbon Black and Confer. Symantec Forces the Industry to Stay Competitive. A Startup’s Opportunity to Thrive.

article thumbnail

Biotech Roundup: Gilead Slump, Celgene Goes Trump, Hemo Data & More

Xconomy

But the company said this week that sales of Sovaldi and Harvoni, which share a common ingredient, sofosbuvir, have slowed with fewer patients starting on the drugs and prices undercut by fierce competition from AbbVie and Merck. But our minds jumped to politics. How about we start a pool? Shares closed Thursday at $9.60

Startup 40
article thumbnail

After “Hubris” and Its HCV Collapse, Can Vertex Avoid Same Mistakes?

Xconomy

Sales of both drugs, ivacaftor (Kalydeco) and the combo pill ivacaftor-lumacaftor (Orkambi), reached almost $1 billion in 2015 and are growing. But the drugs aren’t cures, and competition looms. Telaprevir sales rocketed to nearly $1 billion in the first six months, at the time the fastest drug launch ever.

Startup 40
article thumbnail

Interview with Jason Howe, CEO of Awarepoint

socalTECH

San Diego-based Awarepoint (www.awarepoint.com) is a developer of systems for tracking hospital assets, patients, and doctors, using RFID tags. We were over 2x up on this round, and we also had a bunch of individual investors who wanted to put in--people who had invested in our competition a few years ago. Congrats on funding.

Startup 113
article thumbnail

The Yo-Yo Life of a Tech Entrepreneur – A Cautionary Tale

Both Sides of the Table

TechCrunch Europe ran an article in November of last year that European startups need to work as hard as those in Silicon Valley and I echoed the sentiment in my post about the need for entrepreneurs to be maniacal about their businesses if one wants to work in the hyper competitive tech world. Our first big institutional round was $16.5